Logo image
Human mesenchymal stem cells (MSCs) for treatment towards immune- and inflammation-mediated diseases: review of current clinical trials
期刊文章

Human mesenchymal stem cells (MSCs) for treatment towards immune- and inflammation-mediated diseases: review of current clinical trials

Li-Tzu Wang, Chiao-Hsuan Ting, Men-Luh Yen, Ko-Jiunn Liu, Huey-Kang Sytwu, Kenneth K. WuB Linju Yen
Journal of biomedical science, 卷.23(1), 頁.76
11/2016
PMID: 27809910

摘要

Autoimmune disease Clinical trials Human Immunomodulation Inflammation Mesenchymal stem cells Organ transplantation and rejection Stem cell therapy Endocrinology Diabetes and Metabolism Molecular Biology Clinical Biochemistry Cell Biology Biochemistry (medical) Pharmacology (medical)
Human mesenchymal stem cells (MSCs) are multilineage somatic progenitor/stem cells that have been shown to possess immunomodulatory properties in recent years. Initially met with much skepticism, MSC immunomodulation has now been well reproduced across tissue sources and species to be clinically relevant. This has opened up the use of these versatile cells for application as 3rd party/allogeneic use in cell replacement/tissue regeneration, as well as for immune- and inflammation-mediated disease entities. Most surprisingly, use of MSCs for in immune-/inflammation-mediated diseases appears to yield more efficacy than for regenerative medicine, since engraftment of the exogenous cell does not appear necessary. In this review, we focus on this non-traditional clinical use of a tissue-specific stem cell, and highlight important findings and trends in this exciting area of stem cell therapy.

相關連結

指標

1 檢視次數

詳細資料

Logo image